Therapy in hidradenitis suppurativa

The authors of this prospective, randomised, double-blind, placebo-controlled study in Denmark investigated the efficacy of adalimumab in the treatment of HS. Twenty-one patients were randomised two to one to active treatment with adalimumab 80mg subcutaneously at baseline followed by 40mg subcutaneously every other week for 12 weeks (n = 15) or placebo (n = 6).

After six weeks, a significant reduction in severity of HS was seen and after 12 weeks, the reduction was almost significant. Adalimumab therefore reduces the severity of HS and improves quality of life in patients with this chronic inflammatory disease, the researchers say.
Miller I, Lynggaard CD, Lophaven S et al. Br J Dermatol 2011; 165: 391-8